This considerations document is intended to inform clinical and programmatic decision-making as country programs introduce TLD.
This document supports country program managers to develop clinical guidance and implementation plans for the introduction of the fixed-dose combination tablet of tenofovir, lamivudine and dolutegravir (TLD). It combines summaries of current normative guidance, available evidence, and programmatic considerations to inform the practical decisions that countries will need to make to develop comprehensive guidance on the use of TLD.